Mark Loetzerich earned his PhD in molecular virology from the Ludwig Maximilian University Munich in Germany. With almost 20 years of work experience, he is an expert in the fields of both RNA- and DNA viruses & immunology. In Switzerland Mark worked at 3V Biosciences and specialized on virus-host interactions, cell death, and immune evasion mechanisms of respiratory viruses and possible countermeasures. In the USA Mark lead a highly translational research project at the Hussman Institute in Baltimore linked to viral triggers of multiple sclerosis. Prior joining Cyagen he worked as director for infectious disease for the gene therapy program of UPenn in Philadelphia on a new biologic platform for the treatment of COVID-19 and to transfer this technology to other pandemic viral threads. Mark obtained a post-baccalaureate certificate in biochemical regulatory engineering from the UMBC and was decorated with the Hussman Meritorious Award.